Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Bispecific Anti-VEGF/Angiopoietin-2 antibodies

2 evidence topics · 1 source

Faricimab mechanism of action

“Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2.” (opens the source at this quote in a new tab)

Faricimab indication and extended dosing intervals

“VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD)” (opens the source at this quote in a new tab)

“At week 48, after 4 initial monthly doses in the VABYSMO arm, 45% of patients received the Weeks 28 and 44 dosing, 33% of patients received the Weeks 24, 36 and 48 dosing, and the remaining 22% of patients received dosing every 8 weeks.” (opens the source at this quote in a new tab)